149 related articles for article (PubMed ID: 29542227)
1. Role of Carbamylated Biomolecules in Human Diseases.
Badar A; Arif Z; Alam K
IUBMB Life; 2018 Apr; 70(4):267-275. PubMed ID: 29542227
[TBL] [Abstract][Full Text] [Related]
2. Protein carbamylation in kidney disease: pathogenesis and clinical implications.
Kalim S; Karumanchi SA; Thadhani RI; Berg AH
Am J Kidney Dis; 2014 Nov; 64(5):793-803. PubMed ID: 25037561
[TBL] [Abstract][Full Text] [Related]
3. Protein carbamylation and cardiovascular disease.
Verbrugge FH; Tang WH; Hazen SL
Kidney Int; 2015 Sep; 88(3):474-8. PubMed ID: 26061545
[TBL] [Abstract][Full Text] [Related]
4. Carbamoylation of amino acids and proteins in uremia.
Kraus LM; Kraus AP
Kidney Int Suppl; 2001 Feb; 78():S102-7. PubMed ID: 11168993
[TBL] [Abstract][Full Text] [Related]
5. Could ornithine supplementation be beneficial to prevent the formation of pro-atherogenic carbamylated low-density lipoprotein (c-LDL) particles?
Simsek B; Çakatay U
Med Hypotheses; 2019 May; 126():20-22. PubMed ID: 31010493
[TBL] [Abstract][Full Text] [Related]
6. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies.
Shi J; van Veelen PA; Mahler M; Janssen GM; Drijfhout JW; Huizinga TW; Toes RE; Trouw LA
Autoimmun Rev; 2014 Mar; 13(3):225-30. PubMed ID: 24176675
[TBL] [Abstract][Full Text] [Related]
7. Impaired biological activity of erythropoietin by cyanate carbamylation.
Mun KC; Golper TA
Blood Purif; 2000; 18(1):13-7. PubMed ID: 10686438
[TBL] [Abstract][Full Text] [Related]
8. Post-translational modification derived products (PTMDPs): toxins in chronic diseases?
Gillery P; Jaisson S
Clin Chem Lab Med; 2014 Jan; 52(1):33-8. PubMed ID: 23454717
[TBL] [Abstract][Full Text] [Related]
9. Carbamyl adducts on low-density lipoprotein induce IgG response in LDLR-/- mice and bind plasma autoantibodies in humans under enhanced carbamylation.
Kummu O; Turunen SP; Wang C; Lehtimäki J; Veneskoski M; Kastarinen H; Koivula MK; Risteli J; Kesäniemi YA; Hörkkö S
Antioxid Redox Signal; 2013 Oct; 19(10):1047-62. PubMed ID: 23311771
[TBL] [Abstract][Full Text] [Related]
10. Protein carbamylation links inflammation, smoking, uremia and atherogenesis.
Wang Z; Nicholls SJ; Rodriguez ER; Kummu O; Hörkkö S; Barnard J; Reynolds WF; Topol EJ; DiDonato JA; Hazen SL
Nat Med; 2007 Oct; 13(10):1176-84. PubMed ID: 17828273
[TBL] [Abstract][Full Text] [Related]
11. Impact of fibrinogen carbamylation on fibrin clot formation and stability.
Binder V; Bergum B; Jaisson S; Gillery P; Scavenius C; Spriet E; Nyhaug AK; Roberts HM; Chapple ILC; Hellvard A; Delaleu N; Mydel P
Thromb Haemost; 2017 May; 117(5):899-910. PubMed ID: 28382370
[TBL] [Abstract][Full Text] [Related]
12. The pattern of apolipoprotein A-I lysine carbamylation reflects its lipidation state and the chemical environment within human atherosclerotic aorta.
Battle S; Gogonea V; Willard B; Wang Z; Fu X; Huang Y; Graham LM; Cameron SJ; DiDonato JA; Crabb JW; Hazen SL
J Biol Chem; 2022 Apr; 298(4):101832. PubMed ID: 35304099
[TBL] [Abstract][Full Text] [Related]
13. In vitro inhibition of low density lipoprotein carbamylation by vitamins, as an ameliorating atherosclerotic risk in uremic patients.
Ghaffari MA; Shanaki M
Scand J Clin Lab Invest; 2010 Apr; 70(2):122-7. PubMed ID: 20156036
[TBL] [Abstract][Full Text] [Related]
14. Carbamylation differentially alters type I collagen sensitivity to various collagenases.
Jaisson S; Larreta-Garde V; Bellon G; Hornebeck W; Garnotel R; Gillery P
Matrix Biol; 2007 Apr; 26(3):190-6. PubMed ID: 17156988
[TBL] [Abstract][Full Text] [Related]
15. Evalution of in vitro effect of flavonoids on human low-density lipoprotein carbamylation.
Ghaffari MA; Shanaki M
Iran J Pharm Res; 2010; 9(1):67-74. PubMed ID: 24363709
[TBL] [Abstract][Full Text] [Related]
16. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease.
Ok E; Basnakian AG; Apostolov EO; Barri YM; Shah SV
Kidney Int; 2005 Jul; 68(1):173-8. PubMed ID: 15954906
[TBL] [Abstract][Full Text] [Related]
17. Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein.
Hörkkö S; Huttunen K; Kervinen K; Kesäniemi YA
Eur J Clin Invest; 1994 Feb; 24(2):105-13. PubMed ID: 8206079
[TBL] [Abstract][Full Text] [Related]
18. Carbamylated low-density lipoprotein induces endothelial dysfunction.
Speer T; Owala FO; Holy EW; Zewinger S; Frenzel FL; Stähli BE; Razavi M; Triem S; Cvija H; Rohrer L; Seiler S; Heine GH; Jankowski V; Jankowski J; Camici GG; Akhmedov A; Fliser D; Lüscher TF; Tanner FC
Eur Heart J; 2014 Nov; 35(43):3021-32. PubMed ID: 24658767
[TBL] [Abstract][Full Text] [Related]
19. Endogenous carbamylation of renal medullary proteins.
Claxton JS; Sandoval PC; Liu G; Chou CL; Hoffert JD; Knepper MA
PLoS One; 2013; 8(12):e82655. PubMed ID: 24386107
[TBL] [Abstract][Full Text] [Related]
20. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells.
Asci G; Basci A; Shah SV; Basnakian A; Toz H; Ozkahya M; Duman S; Ok E
Nephrology (Carlton); 2008 Dec; 13(6):480-6. PubMed ID: 18518940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
